Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will participate in two upcoming investor conferences.

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will participate in two upcoming investor conferences. The first is the Stifel 2022 Virtual CNS Day on March 29 at 12:00 p.m. E.T., followed by the 21st Annual Needham Virtual Healthcare Conference on April 11 at 2:15 p.m. E.T. Live webcasts and archived recordings will be accessible on Avadel's Investor Relations website for 90 days post-conference. Avadel focuses on innovative medications like FT218, aimed at treating narcolepsy symptoms.

Argus Session date unavailable

-1.57% session move Open Argus

Details

News Market Reaction – AVDL

The recorded move for AVDL in the trading session of this news was -1.57%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:

• Stifel 2022 Virtual CNS Day: Fireside chat on Tuesday, March 29 at 12:00 p.m. E.T.
• 21^st Annual Needham Virtual Healthcare Conference: Fireside chat on Monday, April 11 at 2:15 p.m. E.T.

Live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Avadel Pharmaceuticals participate in March 2022?

Avadel Pharmaceuticals will participate in the Stifel 2022 Virtual CNS Day on March 29 at 12:00 p.m. E.T.

When is the 21st Annual Needham Virtual Healthcare Conference for Avadel Pharmaceuticals?

The 21st Annual Needham Virtual Healthcare Conference for Avadel Pharmaceuticals is scheduled for April 11, 2022, at 2:15 p.m. E.T.

Where can I find the webcasts for Avadel Pharmaceuticals' investor conferences?

The webcasts will be available on Avadel's Investor Relations website for 90 days after each conference.

What is Avadel Pharmaceuticals focused on?

Avadel Pharmaceuticals focuses on transforming medicines, particularly through innovative solutions for patient treatment challenges.

What is the lead drug candidate of Avadel Pharmaceuticals?

Avadel's lead drug candidate is FT218, designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.